Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
27/04/2022 15:51
April 27 (Reuters) - Paion AG PA8G.DE :
* GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND
COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
* EUR 3.5 MILLION UPFRONT PAYMENT TO PAION
* CRISTÁLIA WILL PAY PAION 20% ROYALTIES ON NET SALES
* CRISTÁLIA INTENDS TO MARKET REMIMAZOLAM IN PROCEDURAL
SEDATION
AND GENERAL ANESTHESIA AND EXPECTS MARKET APPROVAL IN BOTH
INDICATIONS IN BRAZIL IN 2024
Source text for Eikon: ID:nEQ5FTzGza
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022